You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

14 Results
Guidelines and Advice
Status: Archived
ID: 22-2-1
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-2
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-3
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-4
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-5
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-6
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-7
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-8
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-9
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-10
Jun 2014
Guidelines and Advice
Status: Archived
ID: 22-2-M
Jun 2014
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB Limited Use
    lenalidomide - For the treatment of patients with multiple myeloma, who are deemed to be lenalidomide sensitive, and/or has not experienced progression while on a lenalidomide-based regimen in a treatment or maintenance setting, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bortezomib (Unfunded),
lenalidomide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2022

Pages